Zhejiang Starry Pharmaceutical Co.,Ltd. (ZHEJIANG STARRY PHARMACEUTICAL ) aksje

Zhejiang Starry Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical raw materials in China and internationally. It operates through Contrast Agent Series, Quinolone Series, CMO/CDMO, and Others segments. The company offers preparation products comprising iohexol, iopamidol, iodixanol, iomeprol, ioversol, and gadobenate dimeglumine injections; contrast agent APIs and intermediates consisting of iohexol, iopamidol, iodixanol, ioversol, iopromide, iomeprol, gadobenate dimeglumine, gadobutrol, and other products; quinolone APIs and intermediates, such as levofloxacin and levofloxacin hydrochloride; and CMO/CDMO APIs and intermediates, including CIBA, OPAA, 3N, ILC, JSQ, iodine, aza, and loxoprofen sodium. It also engages in technology promotion and application; investment; physical education; and wholesale activities. Zhejiang Starry Pharmaceutical Co.,Ltd. was incorporated in 1997 and is headquartered in Taizhou, China.